Vendor, Morristown, NJ, part of Orexo Ab
Orexo US Inc.
UEI MN1MPMBCVVD5, CAGE 6Y7L3
3 awards and $11,450,712 obligated between January 29, 2024 and September 4, 2026, 100% under full and open competition, against 666.3 offers on average where reported. 9 of the awards trace back to a SAM.gov solicitation on this site.
Sells to
Awarding agencies by dollars.
| Office of Assistant Secretary for Preparedness and Response | $11,450,712 |
| Department of Veterans Affairs | $0 |
Industries
NAICS on the awards, by dollars.
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | $11,450,712 |
| Pharmaceutical Preparation ManufacturingNAICS 325412 | $0 |
| Electromedical and Electrotherapeutic Apparatus ManufacturingNAICS 334510 | $0 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 3 |
| Definitive Contract | 1 |
Hear when Orexo US Inc. wins an award and when a contract it holds is about to end.Follow it
Contracts ending soon
None of Orexo US Inc.'s contracts with a published end date ends in the next 19 months.
Competes with
Vendors selling research and development in biotechnology (except nanobiotechnology) to Office of Assistant Secretary for Preparedness and Response, by dollars.
| Advanced Technology InternationalSummerville, SC | $2,764,576,471 |
| Albert B. Sabin Vaccine Institute, Inc. (The)Washington, DC | $356,898,734 |
| Amgen USA Inc.Thousand Oaks, CA | $345,705,117 |
| Start2 Group, Inc.Cambridge, MA | $227,139,021 |
| Siga Technologies, Inc.New York, NY | $177,835,284 |
| Shionogi Inc.Florham Park, NJ | $156,109,904 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75A50125C00010Definitive Contract, September 24, 2025, Full and Open Competition, 1 offersSolicitation | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | Clinical Development of OX390 (Atipamezole) as an ?2 Agonist Reversal Agent for Human Use to Counteract the Sedative Effects of Xylazine, MeNAICS 541714, PSC AN13 | $11,450,712 |
| 36F79722D0163January 29, 2024, Full and Open Competition, 999 offers | Nac Federal Supply ScheduleDepartment of Veterans Affairs | CancellationNAICS 334510, PSC 6515 | $0 |
| V797D60656November 22, 2024, Full and Open Competition, 999 offers | Nac Federal Supply ScheduleDepartment of Veterans Affairs | 2025 Public Law Pricing UpdateNAICS 325412, PSC 6505 | $0 |
- Places of performance
- New Jersey
- Product and service codes
- AN13 Health R&D Services; Health Care Services; Experimental Development6505 Drugs and Biologicals6515 Medical and Surgical Instruments, Equipment, and Supplies
- Transactions
- 11 across 3 awards